Customer concentration
A single large laboratory customer has represented about 22-23% of revenue and may reduce orders.
- Scope
- Laboratory services revenue
- Materiality
- high
Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based healthcare company with two businesses: laboratory services and therapeutic development. Its core operations provide genetic testing, anatomic pathology, and related laboratory interpretation services, while its therapeutic arm is developing cancer drug candidates using a nanoencapsulation and targeted therapy platform.
−20,8 %
40,6 %
−18,8 %
+13,8 %
6.48
6.48
| % | |
|---|---|
| Laboratory testing services | 85% Genetic, molecular, and anatomic pathology testing sold on a per-test basis to physicians, institutions, and payors. |
| Digital pathology and AI-enabled workflows | 5% Digitized pathology slide review and related technology that supports faster, scalable interpretation. |
| BioPharma services | 5% Technology licensing, CRO-related services, and other revenue tied to pharmaceutical and biotech customers. |
| Therapeutic development | 5% Early-stage oncology drug development using a nanoencapsulation and targeted therapy platform. |
Fulgent sells primarily to insurance payors, institutional customers, and individual payors, with laboratory tests...
- Insurance payorsprimary
Reimburse genetic and pathology tests; pricing and claims processing drive realized revenue.
- Institutional laboratory customersprimary
Buy outsourced testing capacity and specialized assays when internal capabilities are limited.
- Physicians and ordering providerssecondary
Order tests for patient diagnosis and treatment decisions, especially precision diagnostics.
- Pharmaceutical and biotechnology companiessecondary
Buy licensing, CRO-related, and other BioPharma services tied to therapeutic development.
- Individual payorssecondary
Direct consumers or self-pay patients using the company’s testing menu for specific clinical needs.
Fulgent is headquartered in the United States and operates CLIA-licensed laboratories in the U.S...
- •United States is the main operating base and lab footprint
- •CLIA-licensed laboratories support domestic testing services
- •Non-U.S. revenue includes China, Australia, and Canada
- •Puerto Rico and U.S. Virgin Islands are now counted in U.S. revenue
- •International sales add currency and reimbursement exposure
Fulgent is trying to use its scalable testing platform, broad menu, and centralized lab operations to improve margins...
01
Broaden the laboratory customer baseshort-term
Revenue concentration in one large customer creates volatility and can quickly pressure growth.
02
Improve lab efficiency and gross marginmedium-term
Centralized operations and scalable workflows support better unit economics in a price-competitive market.
03
Build therapeutic development into a second platformlong-term
The company wants to diversify beyond diagnostics and create long-term value in oncology.
Fulgent faces customer concentration risk, reimbursement pressure, and regulatory exposure because its testing revenue...
Reimbursement and payor risk
Revenue depends on insurance reimbursement rates, claims processing, and payor audits.
- Scope
- Diagnostic testing collections
- Materiality
- high
Regulatory and licensing compliance
Testing operations require ongoing compliance with federal, state, local, and foreign lab rules.
- Scope
- Laboratory operations
- Materiality
- high
Therapeutic development failure
Early-stage oncology assets may not prove safe, effective, or commercially viable.
- Scope
- R&D and acquired IPR&D
- Materiality
- high
Supplier concentration
The company relies on a limited number of suppliers for reagents and sequencing equipment.
- Scope
- Lab throughput and turnaround times
- Materiality
- medium
Cybersecurity and data privacy
Security incidents could expose sensitive patient data and create liability and reputational damage.
- Scope
- Clinical data and lab systems
- Materiality
- medium
Revenue recognition and variable consideration
Can change reported revenue and bad-debt expense
Credit loss allowance
Affects SG&A and net income
Goodwill and intangible impairment
Can create large non-cash write-downs
Acquired IPR&D valuation
Can materially affect balance sheet and future impairment risk
Gross-margin sharing and licensing revenue timing
Creates quarter-to-quarter volatility
: 28.4.2026